Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy
NCT ID: NCT05107921
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
39 participants
INTERVENTIONAL
2021-11-01
2024-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bromfenac sodium hydrate eye drops
The patients will receive bromfenac sodium hydrate eye drops twice daily for 14 days.
Bromfenac Sodium
The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bromfenac Sodium
The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Needing diode laser photocoagulation
* Consent to the study
Exclusion Criteria
* History of hypersensitivity to bromfenac sodium
* History of hypersensitivity to non-steroidal anti-inflammatory drugs
* Progressive ocular infection
* Liver diseases
* Hypersensitivity to sulfur dioxide
* Receiving anti-coagulation drugs
* History of coagulopathies
1 Month
7 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeong Hun Kim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Hun Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2107-210-1239
Identifier Type: -
Identifier Source: org_study_id